- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05613140
Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure
A Pre-post Analysis of Healthcare Resource Utilization and Costs of Care in a New User Cohort of Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a non-interventional, retrospective cohort study using secondary data sources from the Optum Clinformatics® Data Mart (CDM) and 100% files of the CMS Medicare RIFs.
Two study cohorts were constructed to include adult Heart Failure with reduced ejection fraction (HFrEF) patients who newly initiated sacubitril/valsartan (Cohort 1) and adult Chronic Heart Failure (CHF) patients who newly initiated sacubitril/valsartan (Cohort 2).
The date of first prescription fill for sacubitril/valsartan during the cohort identification period was defined as index date. A 12-month washout period was employed to ascertain the "new user" status. The Healthcare Resource Utilization (HCRU) and costs of care outcomes will be measured within both the 12 months post-index period and the 12 months pre-index period.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
New Jersey
-
East Hanover, New Jersey, United States, 07936-1080
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Cohort 1 - Adult HFrEF patients
- Newly initiated sacubitril/valsartan during the cohort identification period;
- Presence of an International Classification of Diseases, Tenth revision (ICD-10) diagnosis code for systolic HF (I50.1x, I50.2x, I50.4x) on one inpatient hospital claim or two outpatient medical claims during the cohort identification period;
- That are ≥ 18 years old at index date;
- That are treated with sacubitril/valsartan continuously for a minimum of 90-days following treatment initiation;
- That are continuously enrolled in medical and prescription pharmacy benefits in both the pre-index and post-index period, with any gap in coverage of <45 days allowed.
Cohort 2 - Adult CHF patients
- Newly initiated sacubitril/valsartan during the cohort identification period;
- Presence of ICD-10 diagnosis code for systolic HF or diastolic HF (I50.1x, I50.2x, I50.3x, I50.4x) on one inpatient hospital claim or two outpatient medical claims during the cohort identification period;
- That are ≥ 18 years old at index date;
- That are treated with sacubitril/valsartan continuously for a minimum of 90-days following treatment initiation;
- That are continuously enrolled in medical and prescription pharmacy benefits in both the pre-index and post-index period, with any gap in coverage of <45 days allowed.
Exclusion Criteria:
- Patients who died during the post-index period will be excluded.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cohort 1 - Adult HFrEF patients
adult HFrEF patients who newly initiated sacubitril/valsartan
|
Two study cohorts were constructed to include adult HFrEF patients who newly initiated sacubitril/valsartan (Cohort 1) and adult CHF patients who newly initiated sacubitril/valsartan (Cohort 2).
|
Cohort 2 - Adult CHF patients
adult CHF patients who newly initiated sacubitril/valsartan
|
Two study cohorts were constructed to include adult HFrEF patients who newly initiated sacubitril/valsartan (Cohort 1) and adult CHF patients who newly initiated sacubitril/valsartan (Cohort 2).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean number of Heart Failure - specific hospitalizations of adult HFrEF patients treated with sacubitril/valsartan
Time Frame: Baseline, 12 months post initiation of sacubitril/valsartan
|
Number of Heart Failure (HF)-specific hospitalizations was defined as the number of acute inpatient hospitalizations with a primary discharge diagnosis of HF.
An acute inpatient hospitalization was defined as a medical claim for an inpatient hospitalization.
|
Baseline, 12 months post initiation of sacubitril/valsartan
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean number of HF - related hospitalizations of adult HFrEF patients treated with sacubitril/valsartan
Time Frame: Baseline, 12 months post initiation of sacubitril/valsartan
|
Number of HF-related hospitalizations was defined as the number of acute inpatient hospitalizations with a discharge diagnosis of HF in any position.
|
Baseline, 12 months post initiation of sacubitril/valsartan
|
Mean number of all-cause hospitalizations of adult HFrEF patients treated with sacubitril/valsartan
Time Frame: Baseline, 12 months post initiation of sacubitril/valsartan
|
Number of all-cause hospitalizations was as the number of acute inpatient hospitalizations for any reason.
|
Baseline, 12 months post initiation of sacubitril/valsartan
|
Mean number of Urgent Heart Failure (UHF) visits of adult HFrEF patients treated with sacubitril/valsartan
Time Frame: Baseline, 12 months post initiation of sacubitril/valsartan
|
An UHF visit was defined as any of the following: i) a patient with a place of service (POS) code 20, which corresponds to urgent care facility ii) a patient with an ER visit that was outpatient (POS code = 22, 23), identified from revenue codes: 0450, 0451, 0452, 0456 or 0459 iii) a patient with an urgent care clinic visit that was outpatient (POS code = 22, 23), identified from revenue codes: 0516 or 0526 iv) a patient with a hospital observational stay (POS code = 22, 23), identified from revenue code 0762 |
Baseline, 12 months post initiation of sacubitril/valsartan
|
Mean number of Worsening Heart Failure (WHF) episodes of adult HFrEF patients treated with sacubitril/valsartan
Time Frame: Baseline, 12 months post initiation of sacubitril/valsartan
|
Number of WHF episodes was defined as a composite outcome of HF-specific hospitalizations and UHF visits.
|
Baseline, 12 months post initiation of sacubitril/valsartan
|
Mean costs of HF-specific hospitalizations of adult HFrEF patients treated with sacubitril/valsartan
Time Frame: Baseline, 12 months post initiation of sacubitril/valsartan
|
Costs of HF-specific hospitalizations was defined as the sum of payer paid amounts for acute inpatient hospitalizations with a primary discharge diagnosis of HF.
|
Baseline, 12 months post initiation of sacubitril/valsartan
|
Mean costs of HF-related hospitalizations of adult HFrEF patients treated with sacubitril/valsartan
Time Frame: Baseline, 12 months post initiation of sacubitril/valsartan
|
Costs of HF-related hospitalizations were defined as the sum of payer paid amounts for acute inpatient hospitalizations with a discharge diagnosis of HF in any position.
|
Baseline, 12 months post initiation of sacubitril/valsartan
|
Mean costs of all-cause hospitalizations of adult HFrEF patients treated with sacubitril/valsartan
Time Frame: Baseline, 12 months post initiation of sacubitril/valsartan
|
Costs of all-cause hospitalizations were defined as the sum of payer paid amounts for acute inpatient hospitalizations for any reason.
|
Baseline, 12 months post initiation of sacubitril/valsartan
|
Mean costs of UHF visits of adult HFrEF patients treated with sacubitril/valsartan
Time Frame: Baseline, 12 months post initiation of sacubitril/valsartan
|
Costs of UHF visits were defined as the sum of payer paid amounts for UHF visits.
|
Baseline, 12 months post initiation of sacubitril/valsartan
|
Mean costs of WHF episodes of adult HFrEF patients treated with sacubitril/valsartan
Time Frame: Baseline, 12 months post initiation of sacubitril/valsartan
|
Costs of WHF episodes were defined as the sum of payer paid amounts for HF-specific hospitalizations and UHF visits.
|
Baseline, 12 months post initiation of sacubitril/valsartan
|
Mean HF-specific costs of adult HFrEF patients treated with sacubitril/valsartan
Time Frame: Baseline, 12 months post initiation of sacubitril/valsartan
|
HF-related costs were defined as the sum of payer paid amounts for medical claims with a diagnosis of HF in any position.
|
Baseline, 12 months post initiation of sacubitril/valsartan
|
Mean all-cause medical costs of adult HFrEF patients treated with sacubitril/valsartan
Time Frame: Baseline, 12 months post initiation of sacubitril/valsartan
|
All-cause medical costs were defined as the sum of payer paid amounts for all medical claims.
|
Baseline, 12 months post initiation of sacubitril/valsartan
|
Mean all-cause pharmacy costs of adult HFrEF patients treated with sacubitril/valsartan
Time Frame: Baseline, 12 months post initiation of sacubitril/valsartan
|
All-cause pharmacy costs were defined as the sum of payer paid amounts for all pharmacy claims.
|
Baseline, 12 months post initiation of sacubitril/valsartan
|
Mean all-cause total cost of care of adult HFrEF patients treated with sacubitril/valsartan
Time Frame: Baseline, 12 months post initiation of sacubitril/valsartan
|
All-cause total cost of care were defined as the sum of all-cause medical costs and all-cause pharmacy costs.
|
Baseline, 12 months post initiation of sacubitril/valsartan
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLCZ696BUS33
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Heart Failure
-
Maastricht University Medical CenterUniversity College Dublin; RWTH Aachen University; Queen's University, BelfastCompletedChronic Heart FailureNetherlands, Germany, Ireland, United Kingdom
-
Wuerzburg University HospitalRecruitingHeart Failure | Chronic Heart Failure | Chronic Heart DiseaseGermany
-
Lithuanian University of Health SciencesCompletedHeart Failure | Chronic Heart Failure | Congestive Heart Failure | Right Ventricular FailureLithuania
-
Jordan Cardio Vascular Research GroupRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureJordan
-
Zensun Sci. & Tech. Co., Ltd.RecruitingChronic Heart FailureChina
-
University Hospital, Clermont-FerrandHospices Civils de Lyon; University Hospital, Grenoble; Hôpital de la Croix-Rousse and other collaboratorsRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureFrance
-
University of Roma La SapienzaUnknownChronic Heart Failure | Decompensated Heart Failure | Morality
-
University Medicine GreifswaldDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)RecruitingChronic Heart FailureGermany
-
Zensun Sci. & Tech. Co., Ltd.Terminated
-
AquaPass Medical Ltd.CompletedChronic Heart FailureIsrael
Clinical Trials on sacubitril/valsartan
-
Qingdao Central HospitalNot yet recruitingMyocardial Infarction | HypertensionChina
-
Viatris Inc.Not yet recruiting
-
Novartis PharmaceuticalsCompleted
-
Damanhour UniversityTanta UniversityCompleted
-
Novartis PharmaceuticalsCompleted
-
University of Alabama at BirminghamNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular Diseases | Hypertension | Obesity | Nocturnal Blood Pressure | Natriuretic Peptides | Renin-Angiotensin-Aldosterone SystemUnited States
-
Bio-innova Co., LtdNot yet recruiting
-
Novartis PharmaceuticalsCompletedHeart Failure With Preserved Ejection Fraction (HFpEF)United States, Canada
-
Viatris Inc.Not yet recruitingBioequivalence StudyThailand
-
University Hospital, ToulouseTerminated